It was reported here in March 2017 that BioTime, Inc. is conducting a Phase I/IIa clinical trial for OpRegen® for treatment of dry AMD. OpRegen is a retinal pigment epithelium (RPE) stem cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). RPE cells are essential [Read More]
Category: Latest News
The Dangers of Night Driving Glasses
Reprinted courtesy of Laramy-K Optical Lab It is an all too common misconception that yellow tinted or yellow polarized night driving glasses are beneficial for night time driving. The thought is, the yellow or amber color reduces glare and improves contrast. However, in reality, when driving at night or dusk in already limited lighting conditions, [Read More]
Correcting Misconceptions About AMD
(Updated 7/29/19) Age-related macular degeneration (AMD) is a progressive disease of the retina wherein the light-sensing cells in the central area of vision (the macula) stop working and eventually die. The disease is thought to be caused by a combination of genetic and environmental factors, and it is most common in people who are age [Read More]
Charles Bonnet Syndrome Officially Recognized
After years of intensive public education efforts about the causes and symptoms of a mysterious hallucinatory condition affecting visually impaired people, Prevent Blindness and other patient advocacy organizations are pleased that Charles Bonnet Syndrome will soon be officially recognized by eye care professionals around the world. As described in the latest revision of the International [Read More]
Why Do More Women Than Men Have AMD?
Nearly every reliable resource on age-related macular degeneration (AMD) will reveal that more women than men are affected by the disease. Some even go so far as to offer questionable statistics like “About 2/3 of people with AMD are women and 1/3 men”.(1) To explain, writers offer that women live longer than men, or that [Read More]